Based on the key indicators related to Dr Reddys' liquidity, profitability, solvency, and operating efficiency, Dr Reddys Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Dr Reddys' Short and Long Term Debt Total is fairly stable compared to the past year. Other Liabilities is likely to rise to about 3.1 B in 2025, whereas Total Current Liabilities is likely to drop slightly above 69.8 B in 2025. Key indicators impacting Dr Reddys' financial strength include:
The essential information of the day-to-day investment outlook for Dr Reddys includes many different criteria found on its balance sheet. An individual investor should monitor Dr Reddys' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Dr Reddys.
Please note, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Check Dr Reddys' Beneish M Score to see the likelihood of Dr Reddys' management manipulating its earnings.
Dr Reddys Stock Summary
Dr Reddys competes with Pacira BioSciences,, Phibro Animal, Collegium Pharmaceutical, ANI Pharmaceuticals, and Alkermes Plc. Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Dr Reddys Laboratories. It measures of how well RDY is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Dr Reddys brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money RDY had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Dr Reddys has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.
Dr Reddys Laboratories is rated third in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers reporting about 0.54 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Dr Reddys Laboratories is roughly 1.85 . At this time, Dr Reddys' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.
Dr Reddys Laboratories Systematic Risk
Dr Reddys' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dr Reddys volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Dr Reddys Laboratories correlated with the market. If Beta is less than 0 Dr Reddys generally moves in the opposite direction as compared to the market. If Dr Reddys Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dr Reddys Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dr Reddys is generally in the same direction as the market. If Beta > 1 Dr Reddys moves generally in the same direction as, but more than the movement of the benchmark.
Dr Reddys Thematic Clasifications
Dr Reddys Laboratories is part of Obamacare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Companies that count on Obamacare to take off. Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program
This theme covers Companies that count on Obamacare to take off. Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. Get More Thematic Ideas
Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Dr Reddys growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Dr Reddys help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dr Reddys Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dr Reddys Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing RDY Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dr Reddys's daily price indicators and compare them against related drivers.
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.